Vivos Therapeutics, Inc. (VVOS) stock
VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.08−0.00 (-4.64%)
Close on Nov 18, 2026Market cap $1.53MP/E –Yield –
Vivos Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Vivos Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $20.90M, up 45.2% year over year. For fiscal 2025 it was $17.44M, up 16.0% from the year before. The highest annual figure on record is $17.44M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.44M | +16.0% |
| FY2024 | Dec 31, 2024 | $15.03M | +8.9% |
| FY2023 | Dec 31, 2023 | $13.80M | -13.9% |
| FY2022 | Dec 31, 2022 | $16.02M | -5.1% |
| FY2021 | Dec 31, 2021 | $16.89M | +29.2% |
| FY2020 | Dec 31, 2020 | $13.07M | +14.7% |
| FY2019 | Dec 31, 2019 | $11.39M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.15M | +34.9% |
| Q1 FY2026 | Mar 31, 2026 | $5.14M | +70.5% |
| Q4 FY2025 | Dec 31, 2025 | $3.82M | +3.4% |
| Q3 FY2025 | Sep 30, 2025 | $6.78M | +75.7% |
| Q2 FY2025 | Jun 30, 2025 | $3.82M | -5.8% |
| Q1 FY2025 | Mar 31, 2025 | $3.02M | -11.8% |
| Q4 FY2024 | Dec 31, 2024 | $3.70M | +13.9% |
| Q3 FY2024 | Sep 30, 2024 | $3.86M | +16.9% |
| Q2 FY2024 | Jun 30, 2024 | $4.05M | +19.4% |
| Q1 FY2024 | Mar 31, 2024 | $3.42M | -11.4% |
| Q4 FY2023 | Dec 31, 2023 | $3.25M | -17.8% |
| Q3 FY2023 | Sep 30, 2023 | $3.30M | -22.3% |
| Q2 FY2023 | Jun 30, 2023 | $3.40M | -18.9% |
| Q1 FY2023 | Mar 31, 2023 | $3.86M | +5.8% |
| Q4 FY2022 | Dec 31, 2022 | $3.95M | -10.1% |
| Q3 FY2022 | Sep 30, 2022 | $4.25M | -6.6% |
| Q2 FY2022 | Jun 30, 2022 | $4.18M | -7.0% |
| Q1 FY2022 | Mar 31, 2022 | $3.64M | +5.7% |
| Q4 FY2021 | Dec 31, 2021 | $4.39M | +32.9% |
| Q3 FY2021 | Sep 30, 2021 | $4.55M | +38.1% |
| Q2 FY2021 | Jun 30, 2021 | $4.50M | +37.5% |
| Q1 FY2021 | Mar 31, 2021 | $3.45M | +7.9% |
| Q4 FY2020 | Dec 31, 2020 | $3.31M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.29M | – |
| Q2 FY2020 | Jun 30, 2020 | $3.27M | – |
| Q1 FY2020 | Mar 31, 2020 | $3.20M | – |
See a number that looks wrong?